CohBar to Present at H.C. Wainwright 5th Annual NASH Investor Conference
October 05 2021 - 9:00AM
CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company
developing mitochondria based therapeutics to treat chronic
diseases and extend healthy lifespan, announced today that its
Chief Executive Officer, Dr. Joseph Sarret, will present a company
overview at the H.C. Wainwright 5th Annual NASH Investor
Conference, being held virtually on October 12, 2021.
H.C. Wainwright 5th Annual NASH Investor
Conference |
Tuesday, October 12, 2021 at 12:00pm ET |
Webcast: The presentation may be accessed via
webcast at the scheduled time, or following the presentation, using
the following link:
https://journey.ct.events/view/cbeeb31d-02b0-49f5-b232-053031398774 |
A replay of the webcast will be available in the events section
of the CohBar website for two weeks following the presentation.
About CohBar
CohBar (NASDAQ: CWBR) is a clinical stage
biotechnology company focused on the research and development of
mitochondria based therapeutics, an emerging class of drugs for the
treatment of chronic and age-related diseases. Mitochondria based
therapeutics originate from the discovery by CohBar’s founders of a
novel group of naturally occurring mitochondrial-derived peptides
within the mitochondrial genome that regulate metabolism and cell
death, and whose biological activity declines with age. To date,
the company has discovered more than 100 mitochondrial derived
peptides and generated over 1,000 analogs. CohBar’s efforts focus
on the development of these peptides into therapeutics that offer
the potential to address a broad range of diseases, including
nonalcoholic steatohepatitis (NASH), obesity, fibrotic diseases,
cancer, acute respiratory distress syndrome (ARDS), type 2
diabetes, and cardiovascular and neurodegenerative diseases. The
company’s lead compound, CB4211, which is under development for the
treatment of NASH and obesity, completed a successful Phase 1a/1b
clinical trial in August 2021. In addition, CohBar has four
preclinical programs, the most advanced of which is CB5138-3, a
peptide with broad anti-fibrotic and anti-inflammatory properties.
This program is currently in IND-enabling studies with the goal of
filing an IND and initiating a First-in-Human study in 2022 with an
initial indication of idiopathic pulmonary fibrosis. The company
also has a program in ARDS, including COVID-19 associated ARDS, as
well as two peptide families with potential utility in treating
various forms of cancer.
Forward-Looking Statements
This news release contains forward-looking statements that are
not historical facts within the meaning of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements are based
only on our current beliefs, expectations and assumptions regarding
the future of our business, future plans and strategies,
projections, anticipated events and other future conditions. In
some cases you can identify these statements by forward-looking
words such as “believe,” “may,” “will,” “estimate,” “continue,”
“anticipate,” “intend,” “could,” “should,” “would,” “project,”
“plan,” “expect,” “goal,” “seek,” “future,” “likely” or the
negative or plural of these words or similar expressions. Examples
of such forward-looking statements include but are not limited to
statements regarding timing and anticipated outcomes of research
and clinical trials for our mitochondria based therapeutic (MBT)
candidates; expectations regarding the growth of MBTs as a
significant future class of drug products; and statements regarding
anticipated therapeutic properties and potential of our
mitochondrial peptide analogs, MBTs and other potential therapies.
You are cautioned that such statements are not guarantees of future
performance and that actual results or developments may differ
materially from those set forth in these forward-looking
statements. Factors that could cause actual results to differ
materially from these forward-looking statements include: our
ability to successfully advance drug discovery and development
programs, including the delay or termination of ongoing clinical
trials and the timing of announcements and updates relating to our
clinical trials and related data; our possible inability to
mitigate the prevalence and/or persistence of the injection site
reactions, receipt of unfavorable feedback from regulators
regarding the safety or tolerability of CB4211 or the possibility
of other developments affecting the viability of CB4211 or CB5138-3
as a clinical candidate or its commercial potential; results that
are different from earlier data results including less favorable
results that may not support further clinical development; our
ability to raise additional capital when necessary to continue our
operations; our ability to recruit and retain key management and
scientific personnel; the risk that our intellectual property may
not be adequately protected; our ability to establish and maintain
partnerships with corporate and industry partners; and risks
related to the impact on our business of the COVID-19 pandemic or
similar public health crises. Additional assumptions, risks and
uncertainties are described in detail in our registration
statements, reports and other filings with the Securities and
Exchange Commission and applicable Canadian securities regulators,
which are available on our website, and at www.sec.gov or
www.sedar.com.
You are cautioned that such statements are not guarantees of
future performance and that our actual results may differ
materially from those set forth in the forward-looking statements.
The forward-looking statements and other information contained in
this news release are made as of the date hereof and CohBar does
not undertake any obligation to update publicly or revise any
forward-looking statements or information, whether as a result of
new information, future events or otherwise, unless so required by
applicable securities laws. Nothing herein shall constitute an
offer to sell or the solicitation of an offer to buy any
securities.
Contacts: Jordyn TaraziDirector of Investor
RelationsCohBar, Inc.(650) 445-4441Jordyn.tarazi@cohbar.com
Media:Nancy ThompsonVorticom,
Inc.(212)532-2208Nancyt@vorticom.com
CohBar (NASDAQ:CWBR)
Historical Stock Chart
From Jun 2024 to Jul 2024
CohBar (NASDAQ:CWBR)
Historical Stock Chart
From Jul 2023 to Jul 2024